Best Practice & Research Clinical Haematology
Volume 21, Issue 2 , Pages 223-237 , June 2008

Current and novel therapies in acute GVHD

  • Vincent T. Ho, MD (Doctor)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1 617 632 5938; Fax: +1 617 632 5168.
    • ,
  • Corey Cutler, MD, MPH, FRCP(C) (Doctor)

References 

  1. Ferrera JLM, Antin JH. Pathophysiology of graft-versus-host disease. In:  Thomas ED,  Blume KG,  Forman SJ editor. Hematopoietic stem cell transplantation. Boston: Blackwell Scientific Publications; 1999;p. 305–315
  2. Wysocki CA, Jiang Q, Panoskaltsis-Mortari A, et al. Critical role for CCR5 in the function of donor CD4+CD25+regulatory T cells during acute graft-versus-host disease. Blood. 2005;106(9):3300–3307
  3. Deeg HJ. How I treat refractory acute GVHD. Blood. 2007;109(10):4119–4126
  4. Bacigalupo A. Management of acute graft-versus-host disease. British Journal of Haematology. 2007;137(2):87–98
  5. MacMillan ML, Weisdorf DJ, Wagner JE, et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2002;8(7):387–394
  6. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood. 1990;76(8):1464–1472
  7. Van Lint MT, Uderzo C, Locasciulli A, et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood. 1998;92(7):2288–2293
  8. Roy J, McGlave PB, Filipovich AH, et al. Acute graft-versus-host disease following unrelated donor marrow transplantation: failure of conventional therapy. Bone Marrow Transplantation. 1992;10:77–82
  9. Weisdorf D, Haake R, Blazar B, et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood. 1990;75(4):1024–1030
  10. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in recipients of marrow from HLA-matched sibling donors. Transplantation. 1974;18:295–304
  11. Van Lint MT, Milone G, Leotta S, et al. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood. 2006;107(10):4177–4181
  12. Dugan MJ, DeFor TE, Steinbuch M, et al. ATG plus corticosteroid therapy for acute graft-versus-host disease: predictors of response and survival. Annals of Hematology. 1997;75(1–2):41–46
  13. Graziani F, Van Lint MT, Dominietto A, et al. Treatment of acute graft versus host disease with low dose-alternate day anti-thymocyte globulin. Haematologica. 2002;87(9):973–978
  14. Cragg L, Blazar BR, Defor T, et al. A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2000;6(4A):441–447
  15. Lee SJ, Zahrieh D, Agura E, et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood. 2004;104(5):1559–1564
  16. Cahn JY, Bordigoni P, Tiberghien P, et al. Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study. Transplantation. 1995;60(9):939–942
  17. Martin PJ, Nelson BJ, Appelbaum FR, et al. Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Blood. 1996;88(3):824–830
  18. Uberti JP, Ayash L, Ratanatharathorn V, et al. Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2005;11(9):680–687
  19. Hockenbery DM, Cruickshank S, Rodell TC, et al. A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood. 2007;109(10):4557–4563
  20. Carpenter PA, Sanders JE. Steroid-refractory graft-vs.-host disease: past, present and future. Pediatric Transplantation. 2003;7(Suppl. 3):19–31
  21. Hsu B, May R, Carrum G, et al. Use of antithymocyte globulin for treatment of steroid-refractory acute graft-versus-host disease: an international practice survey. Bone Marrow Transplantation. 2001;28(10):945–950
  22. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood. 1991;77(8):1821–1828
  23. Arai S, Margolis J, Zahurak M, et al. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2002;8(3):155–160
  24. Khoury H, Kashyap A, Adkins DR, et al. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin. Bone Marrow Transplantation. 2001;27(10):1059–1064
  25. Remberger M, Aschan J, Barkholt L, et al. Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin. Clinical Transplantation. 2001;15(3):147–153
  26. MacMillan ML, Weisdorf DJ, Davies SM, et al. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2002;8(1):40–46
  27. Knop S, Hebart H, Gscheidle H, et al. OKT3 muromonab as second-line and subsequent treatment in recipients of stem cell allografts with steroid-resistant acute graft-versus-host disease. Bone Marrow Transplantation. 2005;36(9):831–837
  28. Gleixner B, Kolb HJ, Holler E, et al. Treatment of aGVHD with OKT3: clinical outcome and side-effects associated with release of TNF alpha. Bone Marrow Transplantation. 1991;8(2):93–98
  29. Martin P, Schulman H, Schubach W, et al. Fatal Epstein-Barr virus associated proliferation of donor B-cells after treatment of acute graft-versus-host disease with a murine anti-T-cell antibody. Annals of Internal Medicine. 1984;101:310
  30. Knop S, Hebart H, Gratwohl A, et al. Treatment of steroid-resistant acute GVHD with OKT3 and high-dose steroids results in better disease control and lower incidence of infectious complications when compared to high-dose steroids alone: a randomized multicenter trial by the EBMT Chronic Leukemia Working Party. Leukemia. 2007;21(8):1830–1833
  31. Carpenter PA, Appelbaum FR, Corey L, et al. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood. 2002;99(8):2712–2719
  32. Carpenter PA, Lowder J, Johnston L, et al. A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2005;11(6):465–471
  33. Deeg HJ, Blazar BR, Bolwell BJ, et al. Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood. 2001;98(7):2052–2058
  34. Macmillan ML, Couriel D, Weisdorf DJ, et al. A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood. 2007;109(6):2657–2662
  35. Uchiyama T, Broder S, Waldmann TA. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. Journal of Immunology. 1981;126(4):1393–1397
  36. Uchiyama T, Nelson DL, Fleisher TA, et al. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II. Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on one of two types of helper T cells. Journal of Immunology. 1981;126(4):1398–1403
  37. Queen C, Schneider WP, Selick HE, et al. A humanized antibody that binds to the interleukin 2 receptor. Proceedings of the National Academy of Sciences of the United States of America. 1989;86(24):10029–10033
  38. Anasetti C, Martin PJ, Hansen JA, et al. A phase I-II study evaluating the murine anti-IL-2 receptor antibody 2A3 for treatment of acute graft-versus-host disease. Transplantation. 1990;50:49–54
  39. Cuthbert RJG, Phillips GL, Barnett MJ, et al. Anti-interleukin-2 receptor monoclonal antibody (BT 563) in the treatment of severe acute GVHD refractory to systemic corticosteroid therapy. Bone Marrow Transplantation. 1992;10:451–455
  40. Hervé P, Wijdenes J, Bergerat JP, et al. Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10). Blood. 1990;75:1017–1023
  41. Pinana JL, Valcarcel D, Martino R, et al. Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2006;12(11):1135–1141
  42. Bay JO, Dhedin N, Goerner M, et al. Inolimomab in steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: retrospective analysis and comparison with other interleukin-2 receptor antibodies. Transplantation. 2005;80(6):782–788
  43. Anasetti C, Hansen JA, Waldmann TA, et al. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood. 1994;84(4):1320–1327
  44. Willenbacher W, Basara N, Blau IW, et al. Treatment of steroid-refractory acute and chronic graft-versus-host disease with daclizumab. British Journal of Haematology. 2001;112(3):820–823
  45. Przepiorka D, Kernan NA, Ippoliti C, et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood. 2000;95(1):83–89
  46. Massenkeil G, Rackwitz S, Genvresse I, et al. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplantation. 2002;30(12):899–903
  47. Schmidt-Hieber M, Fietz T, Knauf W, et al. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease. British Journal of Haematology. 2005;130(4):568–574
  48. Funke VA, de Medeiros CR, Setubal DC, et al. Therapy for severe refractory acute graft-versus-host disease with basiliximab, a selective interleukin-2 receptor antagonist. Bone Marrow Transplantation. 2006;37(10):961–965
  49. Varadi G, Or R, Slavin S, et al. In vivo CAMPATH-1 monoclonal antibodies: a novel mode of therapy for acute graft-versus-host disease. American Journal of Hematology. 1996;52(3):236–237
  50. Busca A, Locatelli F, Lovisone E, et al. Treatment of severe refractory acute graft-versus-host disease of the gastrointestinal tract with Campath-1H. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2005;11(9):734–736
  51. Wandroo F, Auguston B, Cook M, et al. Successful use of Campath-1H in the treatment of steroid-refractory liver GvHD. Bone Marrow Transplantation. 2004;34(3):285–287
  52. Carella AM, Beltrami G, Scalzulli PR, et al. Alemtuzumab can successfully treat steroid-refractory acute graft-versus-host disease (aGVHD). Bone Marrow Transplantation. 2004;33(1):131–132
  53. Hale G, Jacobs P, Wood L, et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplantation. 2000;26(1):69–76
  54. Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood. 2002;99(12):4357–4363
  55. Shapira MY, Resnick IB, Bitan M, et al. Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: a preliminary report. Bone Marrow Transplantation. 2005;36(12):1097–1101
  56. Toor AA, Stiff PJ, Nickoloff BJ, et al. Alefacept in corticosteroid-refractory graft versus host disease: early results indicate promising activity. The Journal of Dermatological Treatment. 2007;18(1):13–18
  57. Ho VT, Zahrieh D, Hochberg E, et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood. 2004;104(4):1224–1226
  58. Shaughnessey P, Bachier C, Grimley M, et al. Phase II study of denileukin diftitox (ONTAK) in the treatment of steroid resistant acute graft-versus-host disease (AGVHD). Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2003;9(2):110;[abstract]
  59. Busca A, Locatelli F, Marmont F, et al. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid-refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. American Journal of Hematology. 2007;82(1):45–52
  60. Wolff D, Roessler V, Steiner B, et al. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept. Bone Marrow Transplantation. 2005;35(10):1003–1010
  61. Kennedy GA, Butler J, Western R, et al. Combination antithymocyte globulin and soluble TNF alpha inhibitor (etanercept) +/− mycophenolate mofetil for treatment of steroid-refractory acute graft-versus-host disease. Bone Marrow Transplantation. 2006;37(12):1143–1147
  62. Hervé P, Flesch M, Tiberghian P, et al. Phase I–II trial of a monoclonal anti-tumor necrosis factor α antibody for the treatment of refractory severe acute graft-versus-host disease. Blood. 1992;79:3362–3368
  63. Kobbe G, Schneider P, Rohr U, et al. Treatment of severe steroid-refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody. Bone Marrow Transplantation. 2001;28(1):47–49
  64. Jacobsohn DA, Hallick J, Anders V, et al. Infliximab for steroid-refractory acute GVHD: a case series. American Journal of Hematology. 2003;74(2):119–124
  65. Yamane T, Yamamura R, Aoyama Y, et al. Infliximab for the treatment of severe steroid-refractory acute graft-versus-host disease in three patients after allogeneic hematopoietic transplantation. Leukemia & Lymphoma. 2003;44(12):2095–2097
  66. Patriarca F, Sperotto A, Damiani D, et al. Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica. 2004;89(11):1352–1359
  67. Couriel D, Canosa J, Engler H, et al. Early reactivation of cytomegalovirus and high risk of interstitial pneumonitis following T-depleted BMT for adults with hematological malignancies. Bone Marrow Transplantation. 1996;18(2):347–353
  68. Marty FM, Lee SJ, Fahey MM, et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients. A cohort study. Blood. 2003;
  69. Bolanos-Meade J, Jacobsohn DA, Margolis J, et al. Pentostatin in steroid-refractory acute graft-versus-host disease. Journal of Clinical Oncology. 2005;23(12):2661–2668
  70. Basara N, Blau WI, Kiehl MG, et al. Efficacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipient. Transplantation Proceedings. 1998;30(8):4087–4089
  71. Basara N, Kiehl MG, Blau W, et al. Mycophenolate mofetil in the treatment of acute and chronic GVHD in hematopoietic stem cell transplant patients: four years of experience. Transplantation Proceedings. 2001;33(3):2121–2123
  72. Krejci M, Doubek M, Buchler T, et al. Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease. Annals of Hematology. 2005;84(10):681–685
  73. Takami A, Mochizuki K, Okumura H, et al. Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease. International Journal of Hematology. 2006;83(1):80–85
  74. Baudard M, Vincent A, Moreau P, et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients. Bone Marrow Transplantation. 2002;30(5):287–295
  75. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nature Reviews. Cancer. 2004;4(5):335–348
  76. Baan CC, van der Mast BJ, Klepper M, et al. Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. Transplantation. 2005;80(1):110–117
  77. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+regulatory T cells. Blood. 2005;105(12):4743–4748
  78. Zeiser R, Nguyen VH, Beilhack A, et al. Inhibition of CD4+CD25+regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood. 2006;108(1):390–399
  79. Hackstein H, Taner T, Logar AJ, et al. Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells. Blood. 2002;100(3):1084–1087
  80. Monti P, Mercalli A, Leone BE, et al. Rapamycin impairs antigen uptake of human dendritic cells. Transplantation. 2003;75(1):137–145
  81. Hackstein H, Taner T, Zahorchak AF, et al. Rapamycin inhibits IL-4—induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood. 2003;101(11):4457–4463
  82. Chiang PH, Wang L, Liang Y, et al. Inhibition of IL-12 signaling Stat4/IFN-gamma pathway by rapamycin is associated with impaired dendritic [correction of dendritc] cell function. Transplantation Proceedings. 2002;34(5):1394–1395
  83. Woltman AM, de Fijter JW, Kamerling SW, et al. Rapamycin induces apoptosis in monocyte- and CD34-derived dendritic cells but not in monocytes and macrophages. Blood. 2001;98(1):174–180
  84. Woltman AM, van der Kooij SW, Coffer PJ, et al. Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression. Blood. 2003;101(4):1439–1445
  85. Benito AI, Furlong T, Martin PJ, et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation. 2001;72(12):1924–1929
  86. Antin JH, Kim HT, Cutler C, et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood. 2003;102(5):1601–1605
  87. Cutler C, Li S, Ho VT, et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood. 2007;109(7):3108–3114
  88. Wiesmann A, Weller A, Lischka G, et al. Treatment of acute graft-versus-host disease with PUVA (psoralen and ultraviolet irradiation): results of a pilot study. Bone Marrow Transplantation. 1999;23(2):151–155
  89. Furlong T, Leisenring W, Storb R, et al. Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2002;8(4):206–212
  90. Wetzig T, Sticherling M, Simon JC, et al. Medium dose long-wavelength ultraviolet A (UVA1) phototherapy for the treatment of acute and chronic graft-versus-host disease of the skin. Bone Marrow Transplantation. 2005;35(5):515–519
  91. Peritt D. Potential mechanisms of photopheresis in hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2006;12(1 Suppl. 2):7–12
  92. Biagi E, Di Biaso I, Leoni V, et al. Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4+CD25+GITR+Foxp3+CD62L+functional regulatory T-cells in patients with graft-versus-host disease. Transplantation. 2007;84(1):31–39
  93. Greinix HT, Knobler RM, Worel N, et al. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica. 2006;91(3):405–408
  94. Le Blanc K, Ringden O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2005;11(5):321–334
  95. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363(9419):1439–1441
  96. Ringden O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation. 2006;81(10):1390–1397
  97. Shapira MY, Bloom AI, Or R, et al. Intra-arterial catheter directed therapy for severe graft-versus-host disease. British Journal of Haematology. 2002;119(3):760–764
  98. Tfayli A, Selby G, Maqbool F, et al. Role of intra-arterial steroid administration in the management of steroid-refractory acute gastrointestinal graft-versus-host disease. American Journal of Hematology. 2006;81(12):959–962
  99. Bloom AI, Shapira MY, Or R, et al. Intrahepatic arterial administration of low-dose methotrexate in patients with severe hepatic graft-versus-host disease: an open-label, uncontrolled trial. Clinical Therapeutics. 2004;26(3):407–414
  100. Bertz H, Afting M, Kreisel W, et al. Feasibility and response to budesonide as topical corticosteroid therapy for acute intestinal GVHD. Bone Marrow Transplantation. 1999;24(11):1185–1189
  101. Ippoliti C, Champlin R, Bugazia N, et al. Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies. Journal of Clinical Oncology. 1997;15(11):3350–3354
  102. Bianco JA, Higano C, Singer J, et al. The somatostatin analog octreotide in the management of the secretory diarrhea of the acute intestinal graft-versus-host disease in a patient after bone marrow transplantation. Transplantation. 1990;49(6):1194–1195
  103. Nishida T, Hamaguchi M, Hirabayashi N, et al. Intestinal thrombotic microangiopathy after allogeneic bone marrow transplantation: a clinical imitator of acute enteric graft-versus-host disease. Bone Marrow Transplantation. 2004;33(11):1143–1150
  104. Ruutu T, Eriksson B, Remes K, et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood. 2002;100(6):1977–1983

PII: S1521-6926(08)00010-8

doi: 10.1016/j.beha.2008.02.009

Best Practice & Research Clinical Haematology
Volume 21, Issue 2 , Pages 223-237 , June 2008

Article Tools